echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > The world's first case of secondary infection, population immunization and vaccine failure?

    The world's first case of secondary infection, population immunization and vaccine failure?

    • Last Update: 2020-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to Science, a man in Hong Kong was recently diagnosed with neo-crown pneumonia after returning to Hong Kong from Spain, and he recovered in mid-April after contracting neo-crown pneumonia at the end of March, but has now been re-diagnosed.
    The University of Hong Kong's Yuan Guoyong research team confirmed that the man's second infection of the strain genes significantly different, the world's first case of secondary infection, not Fuyang case, causing concern about secondary infection.
    , a clinical microbiologist at the University of Hong Kong (HKU) and one of the authors of the paper on the case, told Science today: "This case proves that at least some patients do not have lifelong immunity.
    " however, the exact discovery is unclear.
    the authors, mass immunity is unlikely to eliminate the spread of SARS-CoV-2, and secondly, vaccines may not provide lifelong protection against COVID-19.
    , a virologist at Columbia University, said it was too early to draw these conclusions.
    I disagree with the full impact on vaccines and immunity," she wrote in an email, as the patients described in the study may be rare examples of people not responding well to first infections.
    Hong Kong University expert Yuan Guoyong said that the patient has a greater chance of re-infection in Europe, and according to the previous wind-induced coronavirus, after infection and has permanent immunity, there is a chance to be infected after a few months, but the second infection is usually no symptoms or mild symptoms, but can still spread the virus between populations.
    Zhang Wenhong, director of the infection department at Huashan Hospital in Shanghai and head of the Xinguan Pneumonia Expert Group, said that earlier there were many reports of Fuyang at home and abroad, but most of them believed to be non-infectious nucleic acid residues, and no evidence of transmission was found, which was considered to be of little clinical significance.
    he believes that the "re-infection" confirmed by HKD needs further research evidence, including virus culture, whether it is a nucleic acid positive or a live virus.
    the full sequence of nucleic acids infected with the virus at the same time.
    also need to look at further academic papers published by HKD.
    that the United States has previously reported re-infection, and ultimately no comprehensive academic report published, it is not enough.
    the world's attention to Fuyang, is afraid of "re-infection."
    "re-infection" is about the durability of immunization, as well as the timing of future vaccine protection and the interval between repeated vaccinations.
    This time the patient recovered four months after the re-infection, or is it a case, this problem should be observed in the larger post-infection population, the world currently has more than 22 million people infected, if "re-infection" is established, then in the new crown high-risk and epidemic areas, re-infection will become the norm. Zhang Wenhong,
    , said that the outside world does not need to be too nervous about this, after all, the history of other common coronavirus, such as colds caused by ordinary coronavirus, after infection immunization time is well over four months.
    the news of "re-infection" in Hong Kong is true, similar reports will appear all over the world in the future, after all, this is a population immunity persistent problem, with universality.
    if no similar cases were reported worldwide, the patient's reporting would have stayed at the news level, not at the academic level.
    source: !-- content presentation ends -- !-- to determine whether the login ends.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.